The group of Pinto is specialized in the genetics of human heart failure genetics and the role of RNAs and their aplication. In 2005, the group of Pinto first published the disproportional rate of sudden death at an early age in carriers of a Lamin A/C mutation. Next, they were the first to suggest a more forceful treatment to prevent sudden death in these LMNA mutation carriers. Having recognized that these patients need a more personalised therapy, the group of Pinto generated a EU Registry to identify the most important risk factors to guide treatment decisions. This has led to changed clinical guidelines on this topic.